The FDA’s new draft guidance mandates Diversity Action Plans for phase 3 clinical trials to ensure participant representation, addressing past underrepresentation and requiring detailed recruitment strategies, though it adds complexity for sponsors.
The FDA’s new draft guidance mandates Diversity Action Plans for phase 3 clinical trials to ensure participant representation, addressing past underrepresentation and requiring detailed recruitment strategies, though it adds complexity for sponsors.